147 related articles for article (PubMed ID: 8646728)
21. Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer.
Kris MG; Gralla RJ; Wertheim MS; Kelsen DP; O'Connell JP; Burke MT; Fiore JJ; Cibas IR; Heelan RT
Cancer Treat Rep; 1986 Sep; 70(9):1091-6. PubMed ID: 3527408
[TBL] [Abstract][Full Text] [Related]
22. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
Buccheri G; Ferrigno D
Eur J Cancer; 1994; 30A(10):1424-31. PubMed ID: 7833096
[TBL] [Abstract][Full Text] [Related]
23. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Masuda N
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
[TBL] [Abstract][Full Text] [Related]
24. The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a phase III randomized FONICAP trial. Italian Lung Cancer Task Force.
De Marinis F; Rinaldi M; Ardizzoni A; Bruzzi P; Pennucci MC; Portalone L; D'Aprile M; Ripanti P; Romano F; Belli M; Altavilla G; Migliorino MR; Rosso R; Salvati F
Tumori; 1999; 85(3):177-82. PubMed ID: 10426128
[TBL] [Abstract][Full Text] [Related]
25. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Berruti A; Bitossi R; Gorzegno G; Bottini A; Alquati P; De Matteis A; Nuzzo F; Giardina G; Danese S; De Lena M; Lorusso V; Farris A; Sarobba MG; DeFabiani E; Bonazzi G; Castiglione F; Bumma C; Moro G; Bruzzi P; Dogliotti L;
J Clin Oncol; 2002 Oct; 20(20):4150-9. PubMed ID: 12377958
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
Buccheri G; Ferrigno D; Rosso A
Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
[TBL] [Abstract][Full Text] [Related]
27. Phase III trial with and without lonidamine in non-small cell lung cancer.
Gatzemeier U; Cavalli F; Häussinger K; Kaukel E; Koschel G; Martinelli G; Neuhauss R; von Pawel J
Semin Oncol; 1991 Apr; 18(2 Suppl 4):42-8. PubMed ID: 1851577
[TBL] [Abstract][Full Text] [Related]
28. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
Dogliotti L; Berruti A; Buniva T; Zola P; Baù MG; Farris A; Sarobba MG; Bottini A; Alquati P; Deltetto F; Gosso P; Monzeglio C; Moro G; Sussio M; Perroni D
J Clin Oncol; 1996 Apr; 14(4):1165-72. PubMed ID: 8648371
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
Gebbia V; Borsellino N; Testa A; Latteri MA; Milia V; Valdesi M; Giotta F; Gebbia N; Colucci G
Anticancer Drugs; 1997 Nov; 8(10):943-8. PubMed ID: 9436637
[TBL] [Abstract][Full Text] [Related]
30. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
Luedke DW; Einhorn L; Omura GA; Sarma PR; Bartolucci AA; Birch R; Greco FA
J Clin Oncol; 1990 May; 8(5):886-91. PubMed ID: 2159054
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
[TBL] [Abstract][Full Text] [Related]
32. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
[TBL] [Abstract][Full Text] [Related]
33. Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial.
Van den Brande P; De Ruysscher D; Vansteenkiste J; Spaas P; Specenier P; Demedts M
Lung Cancer; 1998 Oct; 22(1):45-53. PubMed ID: 9869107
[TBL] [Abstract][Full Text] [Related]
34. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.
Cellerino R; Tummarello D; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
J Clin Oncol; 1991 Aug; 9(8):1453-61. PubMed ID: 1649267
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of soft tissue sarcomas in the adult with a combination of vindesine and cisplatin with doxorubicin or epirubicin: a pilot study].
Becouarn Y; Bui BN; Kerbrat P; Chauvergne J; Brunet R; Robert J
Bull Cancer; 1987; 74(2):109-16. PubMed ID: 3475140
[TBL] [Abstract][Full Text] [Related]
36. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.
Jelić S; Mitrović L; Radosavljević D; Elezar E; Babović N; Kovcin V; Tomasević Z; Kovacević S; Gavrilović D; Radulović S
Lung Cancer; 2001 Oct; 34(1):1-13. PubMed ID: 11557107
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine v no chemotherapy.
Williams CJ; Woods R; Levi J; Page J
Semin Oncol; 1988 Dec; 15(6 Suppl 7):58-61. PubMed ID: 2851181
[TBL] [Abstract][Full Text] [Related]
38. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer.
Murray N; Coppin C; Coldman A; Pater J; Rapp E
J Clin Oncol; 1994 Nov; 12(11):2333-9. PubMed ID: 7964949
[TBL] [Abstract][Full Text] [Related]
39. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
De Lena M; Lorusso V; Bottalico C; Brandi M; De Mitrio A; Catino A; Guida M; Latorre A; Leone B; Vallejo C; Gargano G
J Clin Oncol; 1997 Oct; 15(10):3208-13. PubMed ID: 9336357
[TBL] [Abstract][Full Text] [Related]
40. Five-year survival of nonsmall-cell lung cancer patients after treatment with chemotherapy alone.
Stathopoulos GP
J Clin Oncol; 1990 Mar; 8(3):565-6. PubMed ID: 2155313
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
